Coronary heart disease mortality and hormone therapy before and after the women's health initiative

Obstetrics and Gynecology

Volumn 124, Issue 5, 2014, Pages 947-953

  Tuomikoski, Pauliina ^a,b   Lyytinen, Heli ^a,b   Korhonen, Pasi ^a,b   Hoti, Fabian ^a,b   Vattulainen, Pia ^a,b   Gissler, Mika ^a,b   Ylikorkala, Olavi ^a,b   Mikkola, Tomi S ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; FEMALE; FINLAND; FOLLOW UP; HEART DEATH; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT WITHDRAWAL; YOUNG ADULT; ADVERSE EFFECTS; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ESTROGEN THERAPY; HEALTH PROMOTION; POSTMENOPAUSE; REGISTER; RISK FACTOR; WOMEN'S HEALTH;

ADULT; CAUSE OF DEATH; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FINLAND; HEALTH PROMOTION; HUMANS; POSTMENOPAUSE; REGISTRIES; RISK FACTORS; WOMEN'S HEALTH;

EID: 84925581543     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000461     Document Type: Article

References (28)

1. Rees M. Emerging facade of menopausal hormone therapy. Semin Reprod Med 2010;28:351-9.
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
3. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
4. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmeno-pausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
5. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the perimenopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028-40.
6. Allender S, Scarborough P, Peto V, Rayner M. European Heart Network. European cardiovascular disease statistics 2012. Available at: http://www.ehnheart.org/cvd-statistics.html. Retrieved April 10, 2014.
7. Mikkola TS, Gissler M, Merikukka M, Tuomikoski P, Ylikorkala O. Sex differences in age-related cardiovascular mortality. PLoS One 2013;8:e63347.
8. Guidelines for counselling postmenopausal women about preventive hormone therapy. American College of Physicians. Ann Intern Med 1992;117:1038-41.
9. The North American Menopause Society. Clinical challenges of perimenopause: consensus opinion of the North American menopause society. Available at: http://www.menopause.org/docs/default-document-library/psperimenopause00.pdf?sfvrsn52. Retrieved April 10, 2014.
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-68.
13. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011;43:333-8.
14. Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, et al. The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in post-menopausal women. Maturitas 2003;44:29-38.
15. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
16. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52.
17. The Editorial Committee for Health Statistics in the Nordic Countries. Health statistics in the Nordic countries with data from 2008. Available at: http://www.nowbase.org. Retrieved April 10, 2014.
18. Lahti RA, Sarna S, Penttilä A. Exploitation of autopsy in determining natural cause of death: trends in Finland with special reference to the diagnostics of ischemic heart diseases and cere-brovascular diseases in middle-aged males, 1974-1993. Forensic Sci Int 1998;91:109-21.
19. Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol 2013;142:30-8.
20. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014;174:25-31.
21. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
22. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
23. Lehto HR, Lehto S, Havulinna AS, Ketonen M, Lehtonen A, Kesäniemi YA, et al. Sex differences in short- and long-term case-fatality of myocardial infarction. Eur J Epidemiol 2011;26:851-61.
24. Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamäki H, Rönnback M, et al. Effect of hot flushes on vascular function; a randomized controlled trial. Obstet Gynecol 2009;114:777-85.
25. Lantto H, Haapalahti P, Tuomikoski P, Viitasalo M, Väänänen H, Sovijärvi AR, et al. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. Menopause 2012;19:82-8.
26. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362:2155-65.
27. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18.
28. Mendis S, Puska P, Norrving B, editors. Global atlas on cardiovascular disease prevention and control. Geneva (Switzerland): World Health Organization; 2011. Available at: http://www.who.int/cardiovascular-diseases/publications/atlas-cvd/en/. Retrieved April 10, 2014.